Ulcerative Colitis: Global Drug Forecast and Market Analysis to 2026

Inflammatory bowel disease (IBD) refers to two chronic autoimmune diseases that cause intestinal inflammation: Crohn's disease (CD) and ulcerative colitis (UC). In UC, chronic inflammation affects the colon or large intestines, which are synonymous terms. UC usually manifests initially in the terminal part of the colon, the rectum, and is termed ulcerative proctitis. It can extend to the entire left part of the colon (left-sided proctitis) or the entire colon (pancolitis).

GlobalData estimates the 2016 sales for the UC market at approximately $5.4 billion across the 7MM, encompassing the US, the five major European Union countries (5EU: France, Germany, Italy, Spain, and UK), and Japan. Over the course of the 10-year forecast period, the UC market is expected to grow at a Compound Annual Growth Rate (CAGR) of 2.5% across the 7MM. Each of the 7MM are anticipated to grow, recording CAGRs of 2.7%, 1.2%, and 4.3% across the US, 5EU, and Japan, respectively. At the end of 2026, the US will account for 80.4% of sales across the 7MM, while the 5EU and Japan, will account for around 16.1% and 3.4% of sales, respectively. The higher sales numbers for the US can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of UC in the region, as well as the high annual cost of therapy (ACOT) of J&J’s Stelara and the anticipated ACOT of AbbVie’s risankizumab and Eli Lilly’s mirikizumab in the US market.

Key Questions Answered

How will the UC market landscape in the 7MM (US, France, Germany, Italy, Spain, UK , and Japan) change from 2016–2026?

What are the most promising late-stage pipeline drugs in UC?

How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?

What are the greatest unmet needs in UC? Will the pipeline drugs fulfil these needs of the market?

What are the largest opportunities in the UC landscape?

Scope

Overview of UC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

Topline UC market revenue from 2016–2026. ACOT and major pipeline product sales in this forecast period are included.

Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting UC therapeutics sales in the 7MM.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.

Analysis of the current and future market competition in the global UC therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the UC therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned

J&J

AbbVie

Takeda

Roche

Celgene

Galapagos

Shire

Eli Lilly

Pfizer

EA Pharma

InDex Pharma

J&J

AbbVie

Takeda

Roche

Celgene

Galapagos

Shire

Eli Lilly

Pfizer

EA Pharma

InDex Pharma

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ulcerative Colitis: Executive Summary

2.1 Moderate Growth is Expected for UC Market ...

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Ulcerative Colitis: Executive Summary

2.1 Moderate Growth is Expected for UC Market from 2016–2026

2.2 R&D and Corporate Strategies

2.3 Current and Pipeline Products Partially Address Unmet Needs

2.4 Opportunities for Managing Severe to Fulminant Patients Remain

2.5 Oral Therapies and Biosimilars to Drive Growth in UC Market

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Gut Dysbiosis

4.1.2 The Significance of Diet

4.1.3 The Role of Interleukins

4.1.4 Environmental Factors

4.1.5 Epigenetics

4.1.6 Pathophysiology

4.1.7 Biomarkers/Targets of Interest

4.2 Classification or Staging Systems

4.3 Symptoms

4.4 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for UC (2016–2026)

5.5.1 Diagnosed Incident Cases of UC

5.5.2 Age-Specific Incident Cases of UC

5.5.3 Sex-Specific Incident Cases of UC

5.5.4 Diagnosed Incident Cases of UC by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of UC by Severity

5.5.6 Diagnosed Prevalent Cases of UC

5.5.7 Age-Specific Diagnosed Prevalent Cases of UC

5.5.8 Sex-Specific Diagnosed Prevalent Cases of UC

5.5.9 Diagnosed Prevalent Cases of UC by Severity

5.5.10 Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC

5.5.11 Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC

5.5.12 Comorbidities of UC Among the Diagnosed Prevalent Cases of UC

5.5.13 Undiagnosed Prevalent Cases of UC

5.5.14 Total Prevalent Cases of UC

5.5.15 Diagnosed Incident Cases of IC

5.5.16 Diagnosed Prevalent Cases of IC

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis Overview

6.1.1 Diagnosis

6.2 Treatment Overview

6.3 Treatment Guidelines and Leading Prescribed Drugs

6.3.1 Clinical Practice

6.4 US

6.5 5EU

6.6 Japan

7 Competitive Assessment

7.1 Overview

7.2 5-ASAs

7.2.1 Overview

7.2.2 Efficacy

7.2.3 Safety

7.2.4 SWOT Analysis

7.2.5 Forecast

7.3 Steroids

7.3.1 Overview

7.3.2 Efficacy

7.3.3 SWOT Analysis

7.3.4 Forecast

7.4 Thiopurines

7.4.1 Overview

7.4.2 Efficacy

7.4.3 Safety

7.4.4 SWOT Analysis

7.4.5 Forecast

7.5 Other Immunomodulators

7.5.1 Overview

7.5.2 Efficacy

7.5.3 Safety

7.5.4 SWOT Analysis

7.5.5 Forecast

7.6 Remicade

7.6.1 Overview

7.6.2 Efficacy

7.6.3 Safety

7.6.4 SWOT Analysis

7.6.5 Forecast

7.7 Humira

7.7.1 Overview

7.7.2 Efficacy

7.7.3 Safety

7.7.4 SWOT Analysis

7.7.5 Forecast

7.8 Simponi

7.8.1 Overview

7.8.2 Efficacy

7.8.3 Safety

7.8.4 SWOT Analysis

7.8.5 Forecast

7.9 Entyvio

7.9.1 Overview

7.9.2 Efficacy

7.9.3 Safety

7.9.4 SWOT Analysis

7.9.5 Forecast

7.10 Xeljanz

7.10.1 Overview

7.10.2 Efficacy

7.10.3 Safety

7.10.4 SWOT Analysis

7.10.5 Forecast

7.11 Biosimilar Assessment

7.11.1 Introduction

7.11.2 Pricing of Biosimilars Across the 7MM

7.11.3 Uptake of Biosimilars Across the 7MM

7.12 Infliximab Biosimilars

7.12.1 Overview

7.12.2 Efficacy

7.12.3 Safety

7.12.4 SWOT Analysis

7.12.5 Forecast

7.13 Adalimumab Biosimilars

7.13.1 Overview

7.13.2 Efficacy

7.13.3 Safety

7.13.4 SWOT Analysis

7.13.5 Forecast

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Lack of Safe and Efficacious Treatment Alternatives

8.2.1 Unmet Need

8.2.2 Gap Analysis

8.2.3 Opportunity

8.3 Need for Novel Oral Therapies

8.3.1 Unmet Need

8.3.2 Gap Analysis

8.3.3 Opportunity

8.4 Improved Medical Management for Severe to Fulminant Patients

8.4.1 Unmet Need

8.4.2 Gap Analysis

8.4.3 Opportunity

8.5 Cost of Therapy

8.5.1 Unmet Need

8.5.2 Gap Analysis

8.5.3 Opportunity

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Stelara

9.3.1 Overview

9.3.2 Efficacy

9.3.3 Safety

9.3.4 Dosing and Formulation

9.3.5 Potential Clinical and Commercial Positioning

9.3.6 SWOT Analysis

9.3.7 Forecast

9.4 Etrolizumab

9.4.1 Overview

9.4.2 Efficacy

9.4.3 Safety

9.4.4 Dosing and Formulation

9.4.5 Potential Clinical and Commercial Positioning

9.4.6 SWOT Analysis

9.4.7 Forecast

9.5 Ozanimod Hydrochloride

9.5.1 Overview

9.5.2 Efficacy

9.5.3 Safety

9.5.4 Dosing and Formulation

9.5.5 Potential Clinical and Commercial Positioning

9.5.6 SWOT Analysis

9.5.7 Forecast

9.6 Carotegrast (AJM300)

9.6.1 Overview

9.6.2 Efficacy

9.6.3 Safety

9.6.4 Dosing and Formulation

9.6.5 Potential Clinical and Commercial Positioning

9.6.6 SWOT Analysis

9.6.7 Forecast

9.7 SHP-647

9.7.1 Overview

9.7.2 Efficacy

9.7.3 Safety

9.7.4 Dosing and Formulation

9.7.5 Potential Clinical and Commercial Positioning

9.7.6 SWOT Analysis

9.7.7 Forecast

9.8 Upadacitinib Tartrate

9.8.1 Overview

9.8.2 Efficacy

9.8.3 Safety

9.8.4 Dosing and Formulation

9.8.5 Potential Clinical and Commercial Positioning

9.8.6 SWOT Analysis

9.8.7 Forecast

9.9 Filgotinib

9.9.1 Overview

9.9.2 Efficacy

9.9.3 Safety

9.9.4 Dosing and Formulation

9.9.5 Potential Clinical and Commercial Positioning

9.9.6 SWOT Analysis

9.9.7 Forecast

9.10 Kappaproct

9.10.1 Overview

9.10.2 Efficacy

9.10.3 Safety

9.10.4 Dosing and Formulation

9.10.5 SWOT Analysis

9.11 Risankizumab

9.11.1 Overview

9.11.2 Efficacy

9.11.3 Safety

9.11.4 Dosing and Formulation

9.11.5 Potential Clinical and Commercial Positioning

9.11.6 SWOT Analysis

9.11.7 Forecast

9.12 Mirikizumab

9.12.1 Overview

9.12.2 Efficacy

9.12.3 Safety

9.12.4 Dosing and Formulation

9.12.5 Potential Clinical and Commercial Positioning

9.12.6 SWOT Analysis

9.12.7 Forecast

9.13 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Johnson & Johnson

10.3.1 Overview

10.3.2 Portfolio Assessment

10.3.3 SWOT Analysis

10.4 AbbVie

10.4.1 Overview

10.4.2 Portfolio Assessment

10.4.3 SWOT Analysis

10.5 Takeda Pharmaceuticals

10.5.1 Overview

10.5.2 Portfolio Assessment

10.5.3 SWOT Analysis

10.6 Pfizer

10.6.1 Overview

10.6.2 Portfolio Assessment

10.6.3 SWOT Analysis

10.7 Roche

10.7.1 Overview

10.7.2 Portfolio Assessment

10.7.3 SWOT Analysis

10.8 InDex Pharmaceuticals

10.8.1 Overview

10.8.2 Portfolio Assessment

10.8.3 SWOT Analysis

10.9 Celgene Corporation

10.9.1 Overview

10.9.2 Portfolio Assessment

10.9.3 SWOT Analysis

10.10 EA Pharma

10.10.1 Overview

10.10.2 Portfolio Assessment

10.10.3 SWOT Analysis

10.11 Galapagos

10.11.1 Overview

10.11.2 Portfolio Assessment

10.11.3 SWOT Analysis

10.12 Eli Lilly

10.12.1 Overview

10.12.2 Portfolio Assessment

10.12.3 SWOT Analysis

10.13 Shire

10.13.1 Overview

10.13.2 Portfolio Assessment

10.13.3 SWOT Analysis

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.1.1 Epidemiology Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Patient Segmentation

12.3.4 Percent Drug-Treated Patients

12.3.5 Drugs Included in Each Therapeutic Class

12.3.6 Launch and Patent Expiry Dates

12.3.7 General Pricing Assumptions

12.3.8 Individual Drug Assumptions

12.3.9 Generic Erosion

12.3.10 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for This Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Therapy Area Director

12.6.3 Epidemiologist

12.6.4 Managing Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of Tables

Table 1: Ulcerative Colitis: Key Metrics in the 7MM

Table 2: Truelove and Witts Categorization of Disease Severity and Clinical Parameters

Table 3: Montreal Classification ...

Table 1: Ulcerative Colitis: Key Metrics in the 7MM

Table 2: Truelove and Witts Categorization of Disease Severity and Clinical Parameters

Table 3: Montreal Classification for the Distribution of UC

Table 4: Typical Symptoms of UC

Table 5: Risk Factors and Comorbidities for UC and IBD

Table 6: Truelove and Witts Categorization of Disease Severity and Clinical Parameters

Table 7: Different Guidelines Used for Managing UC

Table 8: Country Profile – US

Table 9: Country Profile – 5EU

Table 10: Country Profile – Japan

Table 11: Leading Treatments for UC, 2017

Table 12: Product Profile – Pentasa

Table 13: Efficacy of Different Drugs in the 5-ASA Class in Inducing Remission in UC Patients

Table 14: Efficacy of Different Drugs in the 5-ASA Class in Preventing Disease Relapse in UC Patients

Table 15: Percentage of Patients Experiencing AEs with 5-ASAs

Table 16: 5-ASA SWOT Analysis, 2018

Table 17: Product Profile – Uceris

Table 18: Efficacy of Uceris

Table 19: Uceris SWOT Analysis, 2018

Table 20: Product Profile – AZA

Table 21: Percentage of Patients Experiencing AEs with AZA and 6-MP Therapy

Table 22: AZA SWOT Analysis, 2018

Table 23: Product Profile – MTX

Table 24: MTX SWOT Analysis, 2018

Table 25: Product Profile – Remicade

Table 26: Efficacy Data for the ACT 1 and ACT 2 Trials

Table 27: Safety of Remicade

Table 28: Remicade SWOT Analysis, 2018

Table 29: Product Profile – Humira

Table 30: Efficacy of Humira – Primary and Secondary

Table 31: Humira SWOT Analysis, 2018

Table 32: Product Profile – Simponi

Table 33: Efficacy of Simponi

Table 34: Safety of Simponi

Table 35: Simponi SWOT Analysis, 2018

Table 36: Product Profile – Entyvio

Table 37: Efficacy of Entyvio

Table 38: Efficacy of Entyvio

Table 39: Safety of Entyvio

Table 40: Entyvio SWOT Analysis, 2018

Table 41: Product Profile – Xeljanz

Table 42: Mean change in Mayo score from OCTAVE Sustain

Table 43: Safety analysis from OCTAVE Induction 1 and 2 Trials

Table 44: Rates of various AEs from OCTAVE Induction 1 and 2

Table 45: Xeljanz SWOT Analysis, 2018

Table 46: Marketed and Pipeline Biosimilars for UC, 2018

Table 47: Average price of Remicade discount accross the 7MM

Table 48: Product Profile – Inflectra/Remsima

Table 49: Infliximab Biosimilars SWOT Analysis, 2018

Table 50: Product Profile – Amjevita

Table 51: Adalimumab Biosimilars SWOT Analysis, 2018

Table 52: Unmet Need and Opportunity in UC, 2017

Table 53: Product Profile – Stelara

Table 54: Stelara SWOT Analysis, 2018

Table 55: Product Profile – Etrolizumab

Table 56: Efficacy Data for Etrolizumab

Table 57: Etrolizumab SWOT Analysis, 2018

Table 58: Product Profile – Ozanimod Hydrochloride

Table 59: Efficacy Analysis of Ozanimod Hydrochloride from the Phase II TOUCHSTONE Trial

Table 60: Summary of the AEs Associated with Ozanimod Use in the TOUCHSTONE Phase ll Trial.

Table 61: Ozanimod SWOT Analysis, 2018

Table 62: Product Profile – Carotegrast

Table 63: Efficacy Analysis of Carotegrast

Table 64: AEs Seen in Patients Treated with Carotegrast and Placebo

Table 65: Carotegrast SWOT Analysis, 2018

Table 66: Product Profile – SHP-647

Table 67: SHP-647 – Remission, Response, and Mucosal Healing Rates at Week 12 with Local Endoscopy Readings

Table 68: SHP-647 SWOT Analysis, 2018

Table 69: Product Profile – Upadacitinib

Table 70: Upadacitinib SWOT Analysis, 2018

Table 71: Product Profile – Filgotinib

Table 72: Filgotinib SWOT Analysis, 2018

Table 73: Product Profile – Kappaproct

Table 74: Safety Data for Kappaproct

Table 75: Kappaproct SWOT Analysis, 2018

Table 76: Product Profile – Risankizumab

Table 77: Phase II Safety Data for Risankizumab in CD

Table 78: Risankizumab SWOT Analysis, 2018

Table 79: Product Profile – Mirikizumab

Table 80: Mirikizumab SWOT Analysis, 2018

Table 81: Drugs in Development for UC, 2018

Table 82: 7MM, Key Companies in the UC Market, 2018

Table 83: J&J’s Disease Portfolio Assessment, 2018

Table 84: J&J SWOT Analysis, 2018

Table 85: AbbVie’s Disease Portfolio Assessment, 2018

Table 86: AbbVie’s SWOT Analysis, 2018

Table 87: Takeda’s Disease Portfolio Assessment, 2018

Table 88: Takeda’s SWOT Analysis, 2018

Table 89: Pfizer’s Disease Portfolio Assessment, 2018

Table 90: Pfizer SWOT Analysis, 2018

Table 91: Roche’s Disease Portfolio Assessment, 2018

Table 92: Roche SWOT Analysis, 2018

Table 93: InDex’s Disease Portfolio Assessment, 2018

Table 94: InDex SWOT Analysis, 2018

Table 95: Celgene’s Disease Portfolio Assessment, 2018

Table 96: Celgene SWOT Analysis, 2018

Table 97: EA Pharma’s Disease Portfolio Assessment, 2018

Table 98: EA Pharma SWOT Analysis, 2018

Table 99: Galapagos’ Disease Portfolio Assessment, 2018

Table 100: Galapagos SWOT Analysis, 2018

Table 101: Eli Lilly’s Disease Portfolio Assessment, 2018

Table 102: Eli Lilly SWOT Analysis, 2018

Table 103: Shire’s Disease Portfolio Assessment, 2018

Table 104: Shire SWOT Analysis, 2018

Table 105: UC Market – Global Drivers and Barriers, 2016–2026

Table 106: Key Events Impacting Sales for UC in the US, 2016–2026

Table 107: UC Market – Global Drivers and Barriers in the US, 2016–2026

Table 108: Key Events Impacting Sales for UC in the 5EU, 2016–2026

Table 109: UC Market – Global Drivers and Barriers in the 5EU, 2016–2026

Table 110: Key Events Impacting Sales for UC in Japan, 2016–2026

Table 111: UC Market – Global Drivers and Barriers in Japan, 2016–2026

Table 112: Key Historical and Projected Launch Dates for UC

Table 113: Key Historical and Projected Patent Expiry Dates for UC

Table 114: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

Figure 1: Global Sales Forecast by Country for UC, 2016 and 2026

Figure 2: Company Portfolio Gap Analysis in UC, 2016–2026

Figure 3: Competitive Assessment ...

Figure 1: Global Sales Forecast by Country for UC, 2016 and 2026

Figure 2: Company Portfolio Gap Analysis in UC, 2016–2026

Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC, 2016–2026

Figure 4: Cellular Mechanisms Involved in the Pathogenesis of UC

Figure 5: Types of UC

Figure 6: 7MM, Age-Standardized Diagnosed Incidence of UC (Cases per 100,000 Population), All Ages, Both Sexes, N, 2016

Figure 7: 7MM, Age-Standardized Diagnosed Prevalence of UC (%), All Ages, Both Sexes, N, 2016

Figure 8: 7MM, Sources Used, Diagnosed Incident Cases of UC

Figure 9: 7MM, Sources Used, Diagnosed Prevalent Cases of UC

Figure 10: 7MM, Sources Used, Undiagnosed Prevalent Cases of UC

Figure 11: 7MM, Sources Used, Total Prevalent Cases of UC

Figure 12: 7MM, Sources Used, Diagnosed Incident Cases of UC by Stage at Diagnosis

Figure 13: 7MM, Sources Used, Diagnosed Incident Cases of UC by Severity

Figure 14: 7MM, Sources Used, Diagnosed Prevalent Cases of UC by Severity

Figure 15: 7MM, Sources Used, Mortality Due to CRC and TMC Among the Diagnosed Prevalent Cases of UC

Figure 16: 7MM, Sources Used, UC Cases Requiring Colectomy Among the Diagnosed Prevalent Cases of UC Due to Failure of Medical Management

Figure 17: 7MM, Sources Used, Diagnosed Incident Cases of IC

Figure 18: 7MM, Sources Used, Diagnosed Prevalent Cases of IC

Figure 19: Diagnosed Incident Cases of UC, 7MM, Men and Women, All Ages, 2016

Figure 20: 7MM, Age-Specific Diagnosed Incident Cases of UC, Both Sexes, N, 2016

Figure 21: 7MM, Sex-Specific Diagnosed Incident Cases of UC, All Ages, N, 2016

Figure 22: 7MM, Diagnosed Incident Cases of UC Segmented by Stage at Diagnosis, Both Sexes, All Ages, N, 2016

Figure 23: 7MM, Diagnosed Incident Cases of UC Segmented by Severity, Both Sexes, All ages, N, 2016

Figure 24: Diagnosed Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016

Figure 25: 7MM, Age-Specific Diagnosed Prevalent Cases of UC, Both Sexes, N, 2016

Figure 26: 7MM, Sex-Specific Diagnosed Prevalent Cases of UC, All Ages, N, 2016

Figure 27: 7MM, Diagnosed Prevalent Cases of UC by Severity, Both Sexes, ≥18 Years, N, 2016

Figure 28: 7MM, Mortality Due to Complications Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016

Figure 29: 7MM, Colectomy Due to Failure of Medical Management Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016

Figure 30: 7MM, Comorbidities Among the Diagnosed Prevalent Cases of UC, Both Sexes, All Ages, N, 2016

Figure 31: Undiagnosed Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016

Figure 32: Total Prevalent Cases of UC, 7MM, Men and Women, All Ages, 2016

Figure 33: Diagnosed Incident Cases of IC, 7MM, Men and Women, All Ages, 2016

Figure 34: Diagnosed Prevalent Cases of IC, 7MM, Men and Women, All Ages, 2016

Figure 35: UC Treatment Algorithm

Figure 36: Unmet Need and Opportunity in UC, 2018

Figure 37: Overview of the Development Pipeline in UC

Figure 38: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for UC in the 7MM During the Forecast Period

Figure 39: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of UC During the Forecast Period

Figure 40: Global Sales of Branded Products for UC by Company in 2016 and 2026

Figure 41: Company Portfolio Gap Analysis in UC During the Forecast Period

Figure 42: Global (7MM) Sales Forecast by Country for UC, 2016 and 2026

Figure 43: Sales Forecast by Class for UC in the US, 2016 and 2026

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Join our mailing list

Saved reports